Compare Recursion Pharmaceuticals Inc (RXRX) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs United Airlines Holdings Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while United Airlines Holdings Inc trades at $118.05 (market cap $38.15B). The key difference: United Airlines Holdings Inc is far larger — about 24.9× Recursion Pharmaceuticals Inc's market cap, and United Airlines Holdings Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | UAL | |
|---|---|---|
Market Cap | $1.53B | $38.15B |
Sector | Health | Industrials |
52-Week High | $6.79 | $136.11 |
52-Week Low | $2.84 | $84.57 |
Enterprise Value | $946.50M | $55.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
United Airlines (UAL) trades at $117.68, up 1.97% on the day, with a bullish technical signal and strong analyst support. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $1.99 exceeding expectations. Revenue growth is robust, reaching $59.07B in 2025, and profitability metrics like a 5.56% net income margin and 23.25% ROE reflect operational strength. Recent news highlights labor agreements and resilient travel demand despite fuel cost pressures.
The outlook for UAL is positive, driven by strong travel demand and premium revenue growth, with a consensus price target of $163.75 implying significant upside. Risks include volatile fuel prices and operational disruptions, but the company's guidance for 2026 EPS of $9–$11 and improving cash flow trends support a favorable investment case for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
